Background {#S4}
==========

Due to their exceptionally high virulence in animals and humans, and their potential for weaponization as aerosols, BP and BPM are both classified as category B bio-threat agents. In addition to use as a countermeasure, *Burkholderia* vaccines would also contribute to improving human health in certain patient populations (such as immunocompromised patients) and sectors of the globe (such as Thailand) most affected by exposure to these pathogens.

Attempts to develop both whole-cell killed and live attenuated vaccines against *Burkholderia* species, have failed to result in a complete protective immune response in mice. Ulrich et al. developed two differently attenuated strains of *B. mallei* (a capsule-negative mutant and a branched-chain amino acid auxotroph) to protect against aerosolized *B. mallei* challenge. No protection was observed to the capsule-negative mutant, but the auxotroph conferred a slight protective advantage although the mice did not clear the infection \[[@R1]\]. Other vaccine targets include the capsular polysaccharides and LPS, as there is significant genetic and structural conservation between the capsular polysaccharides of these species \[[@R2]\]. Recently, subunit vaccines against BC have shown promise. Mice nasally immunized with *Burkholderia multivorans* outer membrane proteins rapidly resolved pulmonary infections following *B. multivorans* challenge and also elicited cross-protection against *B. cenocepacia* \[[@R3], [@R4]\]. Although *B. cepaciae* proteins that appear to be protective have been identified, no vaccine against BC currently exists \[[@R5]\]. To date, no vaccine for any pathogenic *Burkholderia* species is approved for human use.

Although antibodies can protect against severe infection by BM, passive prophylaxis has not been shown to confer sterilizing protective immunity. This is likely due to *Burkholderia's* capability of latent long-term intracellular infections. Cell-mediated immune response, in conjunction with a humoral response, may be required to successfully protect against infection with *Burkholderia* species, and to clear intracellular infections. In general, it is believed that robust cell-mediated immune responses to *Burkholderia* will be required for an effective protective or therapeutic vaccine \[[@R6]\].

Evidence for protective cellular immune response to BPM infection comes from several live attenuated vaccine studies in mice and suggests that cell-mediated immunity is critical. Immunization of C57BL/6 mice with a mutant of BPM (*aroC*) deficient in aromatic amino acid synthesis resulted in sterile immunity \[[@R7]\]. BALB/c mice inoculated with a BPM transposable 2D2 insertion mutant (*ilvl*) auxotrophic for branched chain amino acids induced a protective response and 85% survived a lethal wild type BPM challenge. However, BPM persisted in spleen, liver, kidney and lung tissues up to 30 days post challenge \[[@R8]\]. Splenic BPM-specific T cells, detected in immunized mice, proliferated and produced interferon-gamma *in vitro* in response to dead bacteria. Assessment of T cell antigen specificity indicated that subpopulations of BPM-specific T cells were responsive to secreted proteins. Adoptive immunization of severe combined immunodeficiency mice with T cells from 2D2 live-attenuated BPM mutant-immunized mice resulted in increased survival compared to naïve T cell recipients. This suggests that 2D2 immunization can generate T cell-mediated immunity \[[@R9]\]. CD4+ and CD8+ cell depletion studies argue that CD4+ cells, but not CD8+ cells, mediated this protection *in vivo*.

Cell mediated immune response to antigens produced by live organisms are important to protection from *Burkholderia*. In a separate study, immune responses and resistance following subcutaneous immunization with live BPM were compared with exposure to heat-killed culture filtrate and sonicated BPM antigens. Compared to heat-killed BPM, significant protection was generated in BALB/c mice following exposure to live bacteria. Thus, CD4+ T cells can mediate vaccine-induced immunity to experimental melioidosis \[[@R9]\]. These studies suggest CD4+ T cell recognition of processed and secreted proteins from live bacteria are crucial for disease protection. These results also suggest that the type of immune response generated *in vivo* is influenced by the nature of the BPM antigens, and that immune responses to those proteins that are actively secreted may be required to stimulate a protective immune response \[[@R10]\].

T cell epitopes are critical mediators of cellular immunity and are derived from a pathogen's proteins via two pathways. In one, a protein derived from an intracellular pathogen is processed and its constituent peptides bind to major histocompatability complex (MHC) Class I molecules. Alternatively, proteins derived from pathogens external to the antigen presenting cells (APCs) are processed in the proteolytic compartment; these constituent peptides bind to MHC Class II molecules. After processing and binding, MHC Class I and Class II peptide complexes are then transported to the surface of an APC, where they are exposed to interrogation by passing T cells (CD8+ and CD4+ T cells, respectively). From these different antigen processing and presentation pathways, two different T cell responses are generated: a CD4+ T helper immune response and a CD8+ cytotoxic lymphocyte immune response. After initial exposure to pathogen (or vaccine), memory T cells are established that respond more rapidly and efficiently upon subsequent exposure.

We have previously used this genome-derived epitope-based vaccine design approach to develop a prototype *Francisella tularensis* Type A (subsp. *tularensis*) vaccine that confers 60% protection against heterologous lethal respiratory challenge with the live vaccine strain (LVS), an attenuated subsp. *holarctica* derivative \[[@R11], [@R12]\]. To our knowledge no subunit vaccine for tularemia has achieved a comparable level of protection in this well-developed lethal respiratory challenge model in HLA transgenic mice. In parallel studies, we developed an epitope-based vaccine composed of T cell epitopes derived from sequences conserved between vaccinia and variola. This vaccine was 100% protective against intra-nasal small pox challenge in HLA transgenic mice and occurred in the absence of detectable antibody response \[[@R13]\]. Seven poxvirus genomes were previously the maximum number submitted for analysis by our vaccine design tools. Here we employed the same approach to a much larger set of genomic sequences, with the goal of selecting the optimal sequences for a vaccine that could protect against multiple *Burkholderia* species.

Methods {#S5}
=======

We utilized bioinformatics and immunological tools to identify candidate proteins from 31 *Burkholderia* genomes for inclusion in a multipathogen-specific prophylactic vaccine as previously published \[[@R11], [@R13], [@R14]\]. Details on the approach used for the multipath vaccine are provided below. We then used T cell epitope mapping tools (Conservatrix, EpiMatrix) to identify 9-mer amino acid sequences that were both highly conserved in *Burkholderia* genomes and potentially immunogenic. These putative epitopes were then assembled into immunogenic consensus sequence clusters (using EpiAssembler) and their *in vitro* binding properties tested against 5 human class II HLA alleles. We then hand-selected the best 70 clusters, of which 41 were synthesized for further testing in soluble HLA binding assays as previously described \[[@R11], [@R13]\].

Genome Collection {#S6}
-----------------

Genomes from 31 strains of *Burkholderia* were obtained from Pathema, a proprietary genome database from the J. Craig Venter Institute (<http://pathema.jcvi.org/cgi-bin/Burkholderia>). These included protein-coding genomes from 10 *B. mallei* strains (FMH: 5600 ORFS; NCTC10229: 5519 ORFS; 2002721280: 5519 ORFS; ATCC10399: 5746 ORFS; ATCC23344: 5229 ORFS; GB8: 5936 ORFS; JHU: 5559 ORFS; NCTC10247: 5869 ORFS; PRL-20: 5469 ORFS; and SAVP1: 5200 ORFS), 11 *B. pseudomallei* strains (1106a: 7180 ORFS; 1106b: 7223 ORFS; 1655: 6908 ORFS; 1710a: 7540 ORFS; 406e: 6866 ORFS; 576: 7400 ORFS; 668: 7135 ORFS; K96243: 6304 ORFS; MSHR346: 7588 ORFS; PAS-TEUR52237: 7140 ORFS; S13: 7253 ORFS), 2 *B. ambifaria* strains (AMMD: 6976 ORFS; MC40-6: 7163 ORFS), 2 *B. cenocepacia* strains (AU1054: 7109 ORFS; HI2424: 7227 ORFS), 5 *B. multivorans* strains (ATCC17616-JGI: 6779 ORFS; ATCC17616-Tohoku: 6699 ORFS; CGD1: 6572 ORFS; CGD2: 6653 ORFS; CGD2M: 6646 ORFS) and 1 *B. vietnamiensis* strain. *B. ambifaria*, B*. cenocepacia*, *B. multivorans* and *B. vietnamiensis* (G4: 8423 ORFS) comprise the *Burkholderia cepaciae* complex group \[[@R15]\].

Genome Alignment and Cross-walk {#S7}
-------------------------------

In order to identify proteins conserved within various *Burkholderia* species, the *B. mallei*, *B. pseudomallei* and *B. cepaciae* strains were aligned using GB8, MSHR346 and G4 as reference genomes, respectively. These intra species conserved proteins were then analyzed for inter-species conservation using a comparative genomics tool from Pathema (<http://pathways.jcvi.org/comp-genomics>). This identified proteins in each of the three reference genomes that have hits (defined as any two proteins with a sequence identity greater than or equal to 80%) among the selected comparison genomes.

Secretion Analysis and Conservatrix {#S8}
-----------------------------------

The Phobius program was used to identify single peptides and transmembrane segments and the LipoP program was used to identify lipoprotein attachment sites in proteins from each of the 31 *Burkholderia* genomes (<http://phobius.sbc.su.se/>; <http://www.cbs.dtu.dk/services/LipoP/>) \[[@R16], [@R17]\]. Proteins with a signal sequence, no lipoprotein attachment sites and no more than 1 transmembrane segment were selected for further analysis ([Figure 1](#F1){ref-type="fig"}). In order to target functionally or structurally important epitopes that are conserved between *Burkholderia* species, the Conservatrix algorithm parsed input sequences into component strings, typically comprised of overlapping 9-mer segments, then searched the input database for matching segments found in at least two of the three *Burkholderia* species and ultimately produced a sequence conservation frequency table for each 9-mer.

EpiMatrix Analysis {#S9}
------------------

EpiMatrix, a matrix-based epitope-mapping algorithm, was used to identify Class II HLA epitopes from the conserved 9-mer peptides identified. Potential binding of the 9-mer sequences was scored for 8 common HLA alleles that cover \>90% of the human population (DRB1\*0101, DRB1\*0301, DRB1\*0401, DRB1\*0701, DRB1\*0801, DRB1\*1101, DRB1\*1301 and DRB1\*1501) \[[@R18], [@R19]\]. While assessment scores (Z-scores) range from approximately −3 to +3, Z-scores equal to or greater than 1.64 are generally comprise the top 5% of any given peptide set, are defined as "Hits" and considered potentially immunogenic. Z-scores above 2.32 are in the top 1% and are extremely likely to bind MHC molecule. A 9-mer frame predicted to react to at least 4 different HLA alleles is considered an EpiBar. EpiBars may be the signature feature of highly immunogenic, promiscuous class II epitopes ([Figure 2](#F2){ref-type="fig"}); in previously published studies we have observed that these epitopes tend to be more immunogenic than epitopes that do not contain EpiBars \[[@R11]--[@R13]\].

EpiAssembler and Blastimer {#S10}
--------------------------

EpiAssembler was then used to identify sets of overlapping and conserved epitopes from selected 9-mer peptides, as well as assemble them into extended immunogenic consensus sequences (ICS) \[[@R20]\]. This algorithm iteratively identifies core highly conserved sequences that contain multiple putative T cell epitopes (clusters) and extends the core sequence right and left culling from a database of similarly highly conserved, putatively epitope rich sequences ([Figure 3](#F3){ref-type="fig"}). The EpiMatrix scores within these ICS clusters are then aggregated to create an EpiMatrix Cluster Immunogenicity Score. As cross-reactivity with self may lead to deleterious immune responses, we evaluated the ICS clusters for homology to the human genome by BLAST analysis \[[@R21]\]. Peptides sharing greater than 70% identity with sequences in the human genome were eliminated from consideration. None of the 2,880 *Burkholderia* ICS clusters were found to have significant homology (\>90%) to the human genome.

ICS Selection and Peptide Synthesis {#S11}
-----------------------------------

In order to minimize technical difficulties with peptide synthesis and low water solubility stemming from hydrophobic peptides, the amino acid hydropathy score was assessed for each ICS cluster by GRAVY \[[@R22]\]. Each ICS sequence was constructed to contain a minimal set of T cell epitopes, as well as cover a maximum number of observed *Burkholderia* strains. This was accomplished by comparing the remaining ICS clusters for cross-species conservation. Selected epitopes were synthesized, purified by HPLC and verified by mass spectrometry (21^st^ Century Biochemicals, Marlboro, MA).

Class II HLA binding assay {#S12}
--------------------------

Purified, soluble HLA Class II DR competition binding assays were performed as previously described \[[@R23]\]. Briefly, non-biotinylated ICS peptides over a wide range of concentrations competed with biotinylated influenza hemagglutinin 306--318 standard peptide (0.1 M) for binding to purified DRB1\*0101, DRB1\*0301, DRB1\*0401, DRB1\*0701, and DRB1\*1501 (50 nM) in 96-well plates for 24 hours at 37°C. ELISA plates coated with pan anti-Class II antibodies (L243, anti-HLA-DR; BioXCell, West Lebanon, NH) were blocked with 5% FBS in PBS-0.05% Tween-20 and then bound to the DR/ peptide complexes for 1 hour at 37°C. Following extensive washing in PBS-0.05% Tween-20, the ELISA plates were developed by addition of streptavidin-europium and analyzed on a Victor^3^V Microtiter Plate Reader. Percent inhibition and IC~50~ values of the biotinylated peptide binding were calculated using SigmaPlot 11.1 software.

Results {#S13}
=======

*In silico* epitope mapping {#S14}
---------------------------

### Conservatrix, EpiMatrix {#S15}

Comparative genomic alignment analysis of the *B. mallei* GB8, *B. pseudomallei* MSHR346 and *B. cepaciae* G4 genomes as references yielded a total of 3,288 proteins conserved across all 10 genomes of *B. mallei*, 4,682 proteins conserved across all 11 genomes of *B. pseudomallei* and 2,823 proteins conserved across all 10 genomes of *B. cepaciae*. LipoP and Phobius analyses identified 10,793 secreted core ORFs. Conservatrix analysis of these ORFs yielded 350,004 9-mer peptides; of which 133,469 had perfect conservation across the 10 BM genomes, 175,722 had perfect conservation across the 11 BPM genomes and 40,813 had perfect conservation across the 10 BC genomes. EpiMatrix analyses of these conserved *Burkholderia* 9-mer peptides yielded 54,010 putative Class II HLA epitopes.

### EpiAssembler {#S16}

Using the 54,010 unique 9-mer peptides as a starting point, EpiAssembler produced 2,880 candidate ICS clusters. [Figure 3](#F3){ref-type="fig"} shows a conceptual example of ICS assembly from conserved and overlapping HLA peptide epitopes using EpiAssembler.

### Blastimer {#S17}

Cross-conservation with the human genome may lead to deleterious anti-self immune responses to vaccines. Therefore, we used BLAST analysis to confirm that none of these ICS clusters had any significant homology to the human genome. GRAVY analysis removed 19 ICS clusters with extremely hydrophobic properties. Cross-species conservation analysis yielded 90 ICS epitopes \>70% conserved between *B. mallei* and B*. pseudomallei*, 42 ICS clusters \>70% conserved between *B. mallei* and *B. cepaciae*, 32 ICS clusters \>70% conserved between *B. pseudomallei* and *B. cepaciae* and 20 ICS clusters \>70% conserved among all 3 *Burkholderia* species.

### Protein ontology {#S18}

The top-scoring 70 Class II ICS clusters were selected for further analysis ([Table 1](#T1){ref-type="table"}). These ICS cluster peptides indeed correspond to *Burkholderia* proteins predicted to have a variety of cellular functions ([Figure 4](#F4){ref-type="fig"}). Many of these proteins, such as transmembrane transporters, transmembrane and extracellular receptors, cell wall and membrane biogenesis proteins and flagellar proteins, are predicted to function at the bacterial cell surface, even though they passed the initial screen for putative secreted proteins. In at least four cases, transcription factors have been identified as secreted proteins \[[@R24]--[@R28]\], thus while rare, this is not an unprecedented observation. Based on the previous examples, secretion of these proteins may be indicative of a highly immunogenic protein, therefore we have elected to retain these epitopes in our vaccine development program.

### BLAST against other bacterial proteins {#S19}

A BLAST search was performed for the epitopes identified in this manner against non-human, bactetrial protein. No hits were identified that had greater than 70% conservation (six out of nine amino acid residues conserved). Therefore, these epitopes are relatively unique and unlikely to be cross reactive with other commensals and other pathogens. Vaccination with these epitopes would be expected to drive a pan-*Burkholderia* immune response; that will be the focus of the next stage of our gene-to-vaccine program.

Class II HLA-binding analyses {#S20}
-----------------------------

Peptide binding affinities for HLA DRB\*0101, DRB1\*0301, DRB1\*0401, DRB1\*0701, and DRB1\*1501 were determined in competitive binding assays. Of the 205 ICS peptide-HLA binding interactions assayed, 44% displayed strong binding (IC~50~\<10), 30% showed moderate binding (10\<IC~50~\<100) and 22% displayed weak or non-binding (IC~50~\>100). In only 9 cases, the HLA binding results were inconclusive ([Figure 5](#F5){ref-type="fig"}).

All peptides bound to at least one of the HLA alleles for which they were predicted, 92.7% bound to two alleles for which they were predicted, 82.9% bound to three alleles for which they were predicted. These data support the use of this approach for the high-volume genomic screening for vaccine candidates. Therefore, we proceeded to the next step in our development process with this highly conserved, highly promiscuous candidate epitope cohort.

Comparison between computational predictions and actual *in vitro* HLA binding results show 75.6% overall predictive success rate when excluding inconclusive results ([Figure 6](#F6){ref-type="fig"}). Epitope prediction success was also compared for each class II MHC allele. Successful binding prediction was 76.3% for DRB1\*0101, 59.5% for DRB1\*0301, 82.9% for DRB1\*0401, 78.6% for DRB1\*0701 and 79.5% for DRB1\*1501. A lack of accord between positive binding predictions and actual binding data was observed at 23.7% for DRB1\*0101, 40.5% for DRB1\*0301, 17.1% for DRB1\*0401, 9.5% for DRB1\*0701 and 20.5% for DRB1\*1501 ([Figure 6](#F6){ref-type="fig"}). This could be due to the affinity of the competitor peptide (bound too tightly to compete off), peptide synthesis, problems with peptide aggregation in the *in vitro* assay, or lack of predictive accuracy by the EpiMatrix tool. In a large, retrospective comparison of the EpiMatrix with other online tools, EpiMatrix was as accurate or more accurate than other available epitope prediction tools \[[@R29]\]. Therefore, it is likely that much of the discrepancy between predictions and HLA binding is due to physical interference in the *in vitro* assay.

Discussion {#S21}
==========

Using publically accessible bioinformatics tools we identified secreted proteins conserved between 31 different *Burkholderia* genomes and used our validated vaccine design toolkit to select highly conserved class II epitope clusters as potential T cell epitopes for a T cell directed vaccine. These peptides were then evaluated for their *in vitro* binding properties to 5 different human class II HLA alleles.

*Burkholderia mallei* (BM) and *Burkholderia pseudomallei* (BPM) are responsible for the severe diseases glanders and melioidosis, respectively. *Burkholderia mallei* is a Gram-negative, non-motile bacillus that requires a mammalian host environment for survival (Whitlock et al., 2007). BM is the etiological agent of glanders in donkeys, mules, horses and occasionally humans. Horses are the predominant natural reservoir for BM and transmission to humans occurs through direct contact with infected animals \[[@R30]\]. While BM is generally confined to animal species, it can cause severe respiratory infection when aerosolized and for that reason is considered, along with BPM, a Category B pathogen by the NIAID Biodefense Research Agenda \[[@R31]\].

*Burkholderia pseudomallei,* the etiological agent of melioidosis, is a Gram-negative, facultatively anaerobic, motile bacillus that is responsible for a broad spectrum of illnesses in both humans and animals. The incidence of disease is particularly high in Southeast Asia. In Thailand, an estimated 20% of community-acquired septicemias and approximately 40% of deaths due to complications associated with bacterial sepsis can be attributed to this organism \[[@R32], [@R33]\]. Antibiotic therapy is the first line of defense post-exposure but faces significant challenges. Despite extensive antibiotic regimens, recurrence of infection ranges from 13% to 26% and therapy choice is limited by antibiotic resistance \[[@R32], [@R34], [@R35]\]. As a result, mortality rates as high as 50% in northeast Thailand and \~20% in Northern Australia have been observed \[[@R32], [@R34], [@R36]\]. However, infection with this pathogen in tropical regions of the world may be underreported. Recrudescence may occur: reactivation of latent BPM in Vietnam veterans up to 18 years after their last exposure has been reported \[[@R37]\].

*Burkholderia cepaciae* (BC) is a Gram-negative, non-sporulating motile bacillus found in a variety of both aquatic and terrestrial environments \[[@R38]\]. BC is an opportunistic human pathogen associated with life-threatening pulmonary infections in immunocompromised individuals and individuals with cystic fibrosis \[[@R39]\].

Based on their highly infectious properties in aerosol form and extremely high virulence, BPM and BM are both classified as category B bioterrorist agents. There is currently no vaccine available for any *Burkholderia* species. Due to the potential bioterrorism threat, the development of a safe and effective *Burkholderia* vaccine is a national and worldwide goal. Addition of BC sequences may contribute to the development of a vaccine that could prevent disease in select cystic fibrosis patient populations in the United States.

Conventional vaccines using whole killed, whole protein, or live attenuated have offered success for over a century. However, development of a *Burkholderia* vaccine through this approach has proven elusive. Inactivated whole cell vaccines provided some *Burkholderia* protection in mouse models, but protection in intravenously challenged mice and sterile immunity was unsuccessful \[[@R10], [@R40]--[@R42]\]. Furthermore, killed, whole-cell BM vaccines did not protect the vaccinated mice from a live challenge (\>300 50% lethal doses), suggesting that proteins or polysaccharides that are produced by live bacteria are critically important to protection from BPM and BM disease \[[@R43]\]. BPM vaccine studies using live attenuated virus, killed virus and adoptive immunization provide evidence for CD4+ T cell-mediated vaccine-induced immunity to melioidosis \[[@R9]\]. Despite this progress in vaccine development, *Burkholderia's* propensity for latent infections along with the undefined mechanistic nature behind several attenuated *Burkholderia* strains pose significant challenges towards developing vaccines approved for human use. Contemporary immunome-derived vaccines have a significant advantage over conventional vaccines; the careful selection of the vaccine components through the use of computer-driven analysis should diminish undesired side effects as those observed with whole pathogen and protein subunit vaccines.

This study couples the current boon of genomic resources with our sophisticated bioinformatics and immunoinformatic tools to design candidate peptide epitopes for a multi-species *Burkholderia* vaccine. This approach moves away from whole protein, killed whole cell and attenuated pathogen-based *Burkholderia* vaccines for several reasons. Potentially dangerous cross-reactive or inert space-consuming epitopes present in canonical vaccines are not included in the vaccine. By eliminating superfluous components, epitope-based vaccines maximize their immunogenic payload as well as maximize the protective efficacy to direct a broad based immune response against multiple antigenic proteins associated with the pathogen(s) and also reduce formulation challenges and cost. Safety concerns stemming from the use of intact recombinant proteins that may have undesired biological activities, such as enzymes, immunomodulators, cross-reactivity or toxins, may also be mitigated through targeted epitope approach. These bioinformatics sequence analysis tools, epitope-mapping tools, microarrays and high-throughput immunology assays successfully identified the minimal essential vaccine components for smallpox, tularemia, *Helicobacter pylori* and tuberculosis vaccines \[[@R11]--[@R13]\]. As described here, we are also using this approach for the development of a vaccine for biodefense against multiple *Burkholderia* species. The tools enabling these vaccine development successes are described here, and the anticipated clinical development of immunome-derived and epitope-driven vaccines will be the subject of future reports.

Our results show it is possible to identify and *in vitro* validate T cell epitopes that are conserved across multiple *Burkholderia* species. These epitopes will be further tested in human PBMC and transgenic mice. We aim to use these epitopes for inclusion and further testing in a multi-pathogen-specific *Burkholderia* vaccine. We anticipate that a multi-epitope construct could be administered with an anti-LPS vaccine, already in clinical trial \[[@R44]\], resulting in an effective vaccine directed at providing both humoral and cellular immune response. The resulting multi-pathogen *Burkholderia* vaccine will benefit both the developing world and biodefense.
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![Selection of conserved and secreted *Burkholderia* proteins\
Proteins containing a signal sequence, lacking lipoprotein attachment sites and lacking predicted transmembrane domains were analyzed for conservation across 3 *Burkholderia* reference genomes (*B. mallei* GB8, *B. pseudomallei* MSHR346 and *B. cepaciae* G4).](nihms628401f1){#F1}

![EpiBar located on peptide MP-ICS-CLUSTERS-31-02A\
EpiMatrix analysis of the BPM amino ABC transporter, periplasmic amino acid-binding protein (GenBank ID\# 237814370) identified residues 210--220 within the MP-ICS-CLUSTERS-31-02A peptide as an immunogenic EpiBar. High Z-scores (above 1.64) across 4 or more human class II MHC alleles are considered hits and constitute an EpiBar.](nihms628401f2){#F2}

![Constructing an Immunogenic Consensus Sequence\
(A) EpiAssembler identified a core conserved 9-mer epitope (red) and identified naturally overlapping N- and C-terminal flanking regions from other 9-mer epitopes (orange, green and blue) in a serial fashion to generate a composite immunogenic consensus sequence.](nihms628401f3){#F3}

![Functional classification of identified immunogenic consensus sequence cluster source proteins\
Functional categories are based on cellular biological processes ascertained from manual gene ontology analysis using the UniProt protein database.](nihms628401f4){#F4}

![MHC Class II HLA-binding analysis for promiscuity\
Column 1: Inter-*Burkholderia* species conservation of immunogenic consensus sequence (ICS) peptides (*B. mallei* = BM, *B. pseudomallei* = BPM, *B. cepaciae* = BC); column 2: ICS peptide ID; columns 3--7: ICS peptide binding affinities to the human HLA class II alleles DRB1\*0101, DRB1\*0301 DRB1\*0401 DRB1\*0701 DRB1\*1501. Weak or no affinity (IC~50~\>100 M = white); moderate affinity (100 M \>IC~50~\>10 M = light blue); strong affinity (IC~50~\<10 M = dark blue); inconclusive binding (hash).](nihms628401f5){#F5}

![EpiMatrix binding prediction success\
The HLA class II binding result for each ICS peptide was compared to its EpiMatrix predictive binding scores for each human HLA class II allele. True positives (dark blue) reflect correctly predicted HLA-binding peptide results. False positives (medium blue) reflect incorrectly predicted HLA-binding peptide results. True negatives (light blue) reflect correctly predicted non-HLA-binding peptide results. False negatives (grey) indicate incorrectly predicted non-HLA-binding peptide results.](nihms628401f6){#F6}

###### Class II Epitopes selected for HLA-binding analyses

Column 1: Immunogenic consensus sequence peptide cluster ID; column 2: amino acid sequence for each peptide; column 3: protein description for the parent protein from GenBank; columns 4--6: GenBank ID reference numbers for the reference genomes *B. mallei* (BM) GB8, *B. pseudomallei* (BPM) MSHR346 and *B. cepaciae* (BC) G4.

  CLUSTER LABEL            SEQUENCE                   SOURCE PROTEIN                                                                               GenBank ID               
  ------------------------ -------------------------- -------------------------------------------------------------------------------------------- ------------ ----------- -----------
  BM-BC-02                 GNRALLLLVLAAISLMASRGE      polyhydroxyalkanoate depolymerase                                                            67643796     237811476   134296512
  BM-BPM-07                LKSVLKMVKVYLAVKRRLQPGD     DNA-directed RNA polymerase, beta subunit                                                    67640298     237814156   134294435
  BM-BPM-BC-03             YVERVNVLKLNLALDAAQAALA     K+-transporting ATPase, C subunit                                                            67639435     237811537   134296470
  BM-BPM-01                AFNFVRQFSLNLRADLIGA        oxidoreductase, short-chain dehydrogenase/reductase family protein                           67643921     237813600   134294849
  BM-BC-03                 FAHLKSVLKVLSAFNPSVKGK      BC nitrate/sulfonate/bicarbonate transporter, periplasmic ligand binding protein             67641562     237814431   134294167
  BM-BPM-03                KGEWKLYLHSIRRLLRIDRPGF     Beta-N-acetylhexosaminidase, chitobiase                                                      238561344    237810743   134297015
  BM-BPM-10                PMGVYSKRVNSLAALRARPF       D-methionine ABC transporter, periplasmic D-methionine-binding protein                       67642900     237813281   134295093
  BM-BPM-05                SKLIFSVNSVLAYQAAQQ         cystine-binding periplasmic protein FliY, putative amino acid ABC transporter                238563032    237508413   134293667
  BM-BPM-06                ALVLNVLNAALANNVTLD         glycosy hydrolase family protein                                                             67639146     237812240   134295413
  BM-BPM-BC-05             ALMSILQAMKAAGALRAAAL       flagellar P-ring protein                                                                     238562528    237810465   134297194
  BM-BC-04                 SGIFRGIKRYFSANPPLAKLS      N-acetylmuramoyl-L-alanine amidase AmiC                                                      238561654    237811107   134296748
  BM-BPM-22                MRQFQSIVAQLRAKPLHLM        intracellular PHB depolymerase                                                               67640207     237812617   134288123
  BM-BPM-12                VIPWQMGIVAKLLHVMNSGGFKMK   oxidoreductase, short chain dehydrogenase/reductase family                                   67641011     237810610   134297108
  BM-BPM-18                LEQWLRGVKANLARKATGG        ferric iron uptake ABC transporter (FeT) family, periplasmic iron-binding protein            67639460     237811665   134292266
  BPM-BC-03                RTALQRSRNLVSIRILSLAL       penicillin-binding protein, 1A family                                                        67642044     237812726   134294482
  BM-BPM-19                GSMVASFVLMRLSSVTHTT        ricin-type beta-trefoil lectin domain/galactose oxidase domain protein                       238562996    237508926   134296706
  BM-BC-05                 LPMYTGLHGANRLASNSLLEMA     L-aspartate oxidase                                                                          238562659    237811178   134296677
  BM-BPM-09b               ARGLVYADGILLSNLLGSSYSMT    TonB-dependent receptor                                                                      238562879    237813367   134295041
  BM-BPM-15                SKASKQALNLLVNAKVPTRRA      Phospholipase D (PLD) family protein                                                         67642027     237812695   134295648
  BM-BPM-11                TEPFSAFINVLAHPSAVMI        Glutathione-binding protein GsiB                                                             67642278     237509488   134293406
  BM-BPM-BC-01             KYNDRLSLRRAQAVKSYLV        ompA family protein                                                                          238561689    237813303   134295071
  BM-BPM-02                ANSMNAFRTNRSLSAAHL         hypothetical protein BURPS1655_A2260                                                         67641082     237811791   134295372
  BM-BPM-20                LTRYNRSFFYALAVYQLG         lytic murein transglycosylase B                                                              67642905     237813286   134295088
  BM-BPM-BC-04             VCDKVLSQAKALLAKAG          conserved hypothetical protein                                                               238563606    237811018   134293794
  BPM-BC-05a               QRHLQRMFKVYLNVSPTHYYR      transcriptional regulator, AraC family protein                                               238563940    237510183   134292187
  BPM-BC-01                KIYEMLLAYRIERALTKDQI       penicillin-binding protein, 1A family                                                        238562280    237814104   134294482
  BM-BPM-09a               QAGFRFQHVSNAGILLS          lipid A 3-O-deacylase (PagL) superfamily                                                     238561336    237810753   134297010
  BM-BC-06a                NEFFVPLNVRVQKARRVGAAL      N-acetylmuramoyl-L-alanine amidase                                                           238561654    237811107   134296748
  BM-BC-07                 RNMWQSHRIKLIALSAFTLAE      conserved hypothetical protein                                                               67643124     237814304   134294271
  BM-BPM-08                LFDVSALLNQMRRNPSAYGLST     GDSL-like lipase/acylhydrolase domain/outer membrane autotransporter barrel domain protein   67642947     237812898   134293351
  BPM-BC-08                NPFMMQQALNKLEGKPV          carboxyl-terminal protease                                                                   238563023    237810682   134297049
  BM-BPM-13                RDQVLIRFANRSCSVLVM         ATP-dependent dead/deah box RNA helicase DbpA                                                67639524     237510128   134292614
  BPM-BC-02                LRTLEELARLVRLSQRHLQRLQ     transcriptional regulator, AraC family                                                       238563940    237510183   134292187
  BPM-BC-07                QEQFKLLLIRTYSGALAQ         ABC transporter, periplasmic ligand binding protein, toluene tolerance TtgeD-like protein    67641601     237814073   134294509
  BM-BPM-BC-06             AAAIKYLEALRVELRPA          oxidoreductase, short chain dehydrogenase/reductase family                                   67641011     237810610   134297108
  BM-BPM-BC-09             HHRIYYRLHKLAKQWHAQV        Phosphate regulon sensor protein PhoR                                                        67641079     237811788   134295369
  BM-BPM-BC-08             VTTYLKAVQAAGSTDSLLV        putative amino acid uptake ABC transporter, periplasmic amino acid-binding protein           238561553    237814370   134294218
  BM-BPM-16b               RRRFDVSIALSSLAGGI          conserved hypothetical protein                                                               238561938    237810872   134295646
  BPM-BC-10                YGVIKLNWVILEENVLRQR        mannitol ABC transporter, periplasmic mannitol-binding protein                               67641206     237811073   134296800
  BM-BPM-BC-11             NGNVSSLGNAKSLRGGTL         flagellar basal body P-ring protein (Flgl)                                                   238562528    237810465   134297194
  BM-BC-08                 HPMLYYRALTQGLNQTLA         tRNA delta(2)-isopentenylpyrophosphate transferase                                           67642140     237813667   134294835
  BM-BPM-BC-13             NKILRAFLKSKGVKDS           putative amino acid ABC transporter, periplasmic amino acid-binding protein                  67644003     237813471   134294953
  BM-BPM-BC-14             LQNFYVLTRYNRSADVKRFI       lytic murein transglycosylase B                                                              67642905     237813286   134295088
  BM-BC-09                 DYIYQKLLGVRGVFA            Tol-Pal system beta propeller repeat protein Tol                                             238561025    237813605   134294844
  BM-BPM-24b               ARGFILGLANAGGD             branched-chain amino acid ABC transporter                                                    238561553    237814370   134294218
  BM-BPM-BC-15             TLRIRGLHNAANALAAVS         UDP-N-acetylmuramoyl-L-alanyl-D-glutamate synthetase                                         238561283    237813921   134294645
  BM-BPM-04a               NAAFNFNNAIRFTSVFP          outer membrane porin protein                                                                 238561395    237509809   134295282
  BPM-BC-05b               GTAIYYRLHKLAKQWHAQV        phosphate regulon sensor kinase PhoR                                                         67641079     237811788   134295369
  BPM-BC-09b               AEVALQRSLPAPAAH            tetratricopeptide repeat protein                                                             238561327    237810775   134296995
  BM-BPM-21                NVCQLRVSRNALASIAVL         putative lipoprotein, parallel beta-helix repeat protein                                     67642171     237811603   134296638
  MP-ICS-CLUSTERS-31-02A   ASDFSSFLLQAQSSKAQILGLA     ABC branched-chain amino acid family transporter                                             238561553    237814370   134294218
  MP-ICS-CLUSTERS-31-03    GEPRVNVLKLNLALDAAQAAH      K+-transporting ATPase, C subunit (kdpC)                                                     67639435     237811537   134296470
  MP-ICS-CLUSTERS-31-01    KKNFTAMLRLDHNRALSQLAA      malate dehydrogenase                                                                         67642757     237508279   134293103
  MP-ICS-CLUSTERS-31-06    TQTLANMLANLGISINNGSANG     flagellar P-ring protein Flgl (flgl)                                                         238562528    237810465   134297194
  MP-ICS-CLUSTERS-31-02B   RAAAKVILNARTGSIVMNQ        flagellar P-ring protein (flgl)                                                              238562528    237810465   134297194
  MP-ICS-CLUSTERS-31-04B   SNPYKLDVAKAKALLAKAG        ABC transporter, periplasmic substrate-binding protein                                       238563343    237508894   134293794
  MP-ICS-CLUSTERS-31-05    PRSYFRGLNFLLNEQP           tetratricopeptide repeat protein                                                             67642911     237813292   134295082
  MP-ICS-CLUSTERS-31-12    LERFGRYHATLSPGLNIV         SPFH domain protein/band 7 family protein                                                    67641689     237812784   134296009
  MP-ICS-CLUSTERS-31-11B   ALNDRLMLAYLTKNAQLPLRPG     amino acid ABC transporter, periplasmic amino acid-binding protein                           67640271     237812103   134295624
  MP-ICS-CLUSTERS-31-08    TAAIKGMVSSLDPHSSYLDK       carboxyl-terminal protease \[3.4.21.-\]                                                      238563023    237810682   134297049
  MP-ICS-CLUSTERS-31-11A   TVELHFALGNLFRRR            tetratricopeptide repeat protein                                                             67642911     237813292   134295082
  MP-ICS-CLUSTERS-31-09    VPTLQKNAVPKLVDGA           conserved hypothetical protein                                                               238561685    237813300   134295073
  MP-ICS-CLUSTERS-31-16    ARGVRGIINFSGGLRQDLCEG      conserved hypothetical protein                                                               67641022     237810595   134297116
  MP-ICS-CLUSTERS-31-20    GETYTASVRMQLDTALMPKPF      conserved hypothetical protein                                                               67642458     237810345   134297371
  MP-ICS-CLUSTERS-31-04A   ARQFKSLEDLKGKKL            amino acid ABC transporter, periplasmic amino acid-binding protein                           67640271     237812103   134295624
  MP-ICS-CLUSTERS-31-13    DDGIKGMLGHFNSGTTIPASRI     putative periplasmic substrate-binding protein                                               67643100     237814333   134294246
  MP-ICS-CLUSTERS-31-18    REKMKKLYAPFNRNHERTIYMDV    UDP-glucose 6-dehydrogenase (udg)                                                            67642910     237813291   134295083
  MP-ICS-CLUSTERS-31-15    DNNFRYSRAVLDACL            ADP-L-glycero-D-manno-heptose-6-epimerase (rfaD)                                             67642908     237813289   134295085
  MP-ICS-CLUSTERS-31-14    VEGVRVLAGVNLPMLVRA         PTS system, mannose/fructose/sorbose (Man                                                    67640741     237810677   134297053
  MP-ICS-CLUSTERS-31-19    VPSYVYQAGLKSFDDI           ABC transporter, quaternary amine uptake transporter (QAT) family                            238563533    237509058   134292111
